These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 11943320)
1. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? Arai M; Earl DD; Yamamoto JK Vet Immunol Immunopathol; 2002 Mar; 85(3-4):189-204. PubMed ID: 11943320 [TBL] [Abstract][Full Text] [Related]
2. Reduced provirus burden and enhanced humoral immune function in AZT-treated SCID-feline mice inoculated with feline immunodeficiency virus. Johnson CM; Selleseth DW; Ellis MN; Childers TA; Tompkins MB; Tompkins WA Vet Immunol Immunopathol; 1995 May; 46(1-2):169-80. PubMed ID: 7618256 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of different antiretroviral drug protocols on naturally infected feline immunodeficiency virus (FIV) cats in the late phase of the asymptomatic stage of infection. Gómez NV; Fontanals A; Castillo V; Gisbert MA; Suraniti A; Mira G; Pisano PB Viruses; 2012 Jun; 4(6):924-39. PubMed ID: 22816032 [TBL] [Abstract][Full Text] [Related]
6. Follow-up on long-term antiretroviral therapy for cats infected with feline immunodeficiency virus. Medeiros Sde O; Abreu CM; Delvecchio R; Ribeiro AP; Vasconcelos Z; Brindeiro Rde M; Tanuri A J Feline Med Surg; 2016 Apr; 18(4):264-72. PubMed ID: 25855689 [TBL] [Abstract][Full Text] [Related]
7. Effect of 3'azido-2',3'-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats. Smyth NR; Bennett M; Gaskell RM; McCracken CM; Hart CA; Howe JL Res Vet Sci; 1994 Sep; 57(2):220-4. PubMed ID: 7817010 [TBL] [Abstract][Full Text] [Related]
8. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Hartmann K; Donath A; Beer B; Egberink HF; Horzinek MC; Lutz H; Hoffmann-Fezer G; Thum I; Thefeld S Vet Immunol Immunopathol; 1992 Dec; 35(1-2):167-75. PubMed ID: 1363008 [TBL] [Abstract][Full Text] [Related]
9. Virulence differences between two field isolates of feline immunodeficiency virus (FIV-APetaluma and FIV-CPGammar) in young adult specific pathogen free cats. Pedersen NC; Leutenegger CM; Woo J; Higgins J Vet Immunol Immunopathol; 2001 May; 79(1-2):53-67. PubMed ID: 11356250 [TBL] [Abstract][Full Text] [Related]
10. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus. Lehmann R; von Beust B; Niederer E; Condrau MA; Fierz W; Aubert A; Ackley CD; Cooper MD; Tompkins MB; Lutz H Vet Immunol Immunopathol; 1992 Dec; 35(1-2):199-214. PubMed ID: 1363009 [TBL] [Abstract][Full Text] [Related]
11. Effects of incidental infections and immune activation on disease progression in experimentally feline immunodeficiency virus-infected cats. Reubel GH; Dean GA; George JW; Barlough JE; Pedersen NC J Acquir Immune Defic Syndr (1988); 1994 Oct; 7(10):1003-15. PubMed ID: 7916048 [TBL] [Abstract][Full Text] [Related]
13. Ability of CD8(+) T cell anti-feline immunodeficiency virus activity correlated with peripheral CD4(+) T cell counts and plasma viremia. Hohdatsu T; Yamazaki A; Yamada M; Kusuhara H; Kaneshima T; Koyama H Microbiol Immunol; 2003; 47(10):765-73. PubMed ID: 14605443 [TBL] [Abstract][Full Text] [Related]
14. Prior Puma Lentivirus Infection Modifies Early Immune Responses and Attenuates Feline Immunodeficiency Virus Infection in Cats. Sprague WS; Troyer RM; Zheng X; Wood BA; Macmillian M; Carver S; VandeWoude S Viruses; 2018 Apr; 10(4):. PubMed ID: 29677149 [TBL] [Abstract][Full Text] [Related]
15. Ability of CD8+ T cell anti-feline immunodeficiency virus (FIV) activity and FIV proviral DNA load in mononuclear cells in FIV-infected cats. Hohdatsu T; Nakanishi T; Saito I; Koyama H J Vet Med Sci; 2005 Jan; 67(1):129-31. PubMed ID: 15699611 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and adverse effects of the antiviral compound plerixafor in feline immunodeficiency virus-infected cats. Hartmann K; Stengel C; Klein D; Egberink H; Balzarini J J Vet Intern Med; 2012; 26(3):483-90. PubMed ID: 22551322 [TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of FIV-pPPR, a pathogenic molecular clone of feline immunodeficiency virus, and two drug-resistant pol gene mutants. McCrackin Stevenson MA; McBroom DG Am J Vet Res; 2001 Apr; 62(4):588-94. PubMed ID: 11327469 [TBL] [Abstract][Full Text] [Related]
18. Antiviral therapy reduces viral burden but does not prevent thymic involution in young cats infected with feline immunodeficiency virus. Hayes KA; Phipps AJ; Francke S; Mathes LE Antimicrob Agents Chemother; 2000 Sep; 44(9):2399-405. PubMed ID: 10952586 [TBL] [Abstract][Full Text] [Related]
19. Involvement of cytolytic and non-cytolytic T cells in the control of feline immunodeficiency virus infection. Flynn JN; Dunham S; Mueller A; Cannon C; Jarrett O Vet Immunol Immunopathol; 2002 Mar; 85(3-4):159-70. PubMed ID: 11943317 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of CD4%:CD8 low% T-lymphocyte ratio to differentiate feline immunodeficiency virus (FIV)-infected from FIV-vaccinated cats. Litster A; Lin JM; Nichols J; Weng HY Vet Microbiol; 2014 Jun; 170(3-4):197-205. PubMed ID: 24559863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]